- ENESTnd data indicate trend for longer overall survival and event-free survival in newly diagnosed Ph+ CML patients on Tasigna versus Gleevec(1)... ...http://in.sys-con.com/node/2889561
By Bill Berkrot (Reuters) - A closely watched leukemia drug developed by Johnson & Johnson and Pharmacyclics Inc maintained its effectiveness in... ...http://in.reuters.com/article/2013/12/08/us-pharmacyclics-johnsonandjohnson-leuke-idINBRE9B706D20131208?feedType=RSS&feedName=health
NEW ORLEANS, Dec. 8, 2013 /PRNewswire-USNewswire/ -- A series of studies presented today during the 55th American Society of Hematology Annual... ...http://in.sys-con.com/node/2889523
By the third evening of the American Studies Association 's national conference, a petition calling for the boycott of Israeli academic... ...http://www.universitiesnews.com/2013/12/08/palestinian-activism-grows-at-us-universities/
Three and a half years after beginning a clinical trial which demonstrated the first successful and sustained use of genetically engineered T cells... ...http://www.medindia.net/news/report-on-progress-of-first-59-leukemia-patients-who-received-cell-therapy-128845-1.htm
Prostate cancer is the second leading...